ALMS
NASDAQ HealthcareAlumis Inc. - Common Stock
Biotechnology
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $24.99 |
|---|---|
| 成交量 | 1,156,523 |
| 市值 | 3.18B |
| RSI（14日） | 50.7 |
| 200日均线 | $12.55 |
| 50日均线 | $25.68 |
| 52周最高 | $30.60 |
| 52周最低 | $2.76 |
| Forward P/E | -7.73 |
| Price / Book | 8.68 |
🎯 投资策略评分
ALMS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (50/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🎈 Over-Hyped (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ALMS in your text
粘贴任何文章、记录或帖子 — 工具将提取 ALMS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.